SecBot SecBot
SECBOTREPLAY Home › Report › ABCL

ABCL · AbCellera Biologics Inc

AbCellera Biologics Inc. · 424B5 filed Aug 11, 2026 at 16:59 ET

At the news

BEARISHIMPACT 7/10

424B5 filed Aug 11, 2026 at 16:59 ET

AbCellera Biologics Inc. filed a preliminary prospectus supplement for a $200 million underwritten public offering of common shares and pre-funded warrants. The offering follows positive Phase 2 data for its lead drug candidate, ABCL635, announced on August 10, 2026. The dilutive capital raise, coming on the heels of a positive catalyst, signals a need for cash to fund clinical development and will significantly dilute existing shareholders at a ~$9.32 reference price, creating a bearish near-term dynamic despite the positive clinical news.

  • AbCellera is offering $200,000,000 of common shares and pre-funded warrants.
  • The offering is priced at an undisclosed amount; the last reported sale price on August 10, 2026 was $9.32 per share.
  • Net tangible book value as of June 30, 2026 was $811.7 million, or $2.65 per share, implying substantial dilution for new investors.
  • Proceeds will fund continued R&D and clinical advancement of the internal pipeline, including lead program ABCL635.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access